Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
Roughly 30 million people in the United States are living with a rare disorder, facing challenges such as affordable and timely access to therapies, provider networks, coverage, care coordination and clinical expertise. Last fall, stakeholders met virtually for an Academy of Managed Care Pharmacy Partnership Forum to discuss viable solutions to these challenges.
It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and even disease prevalence.
Finding consensus among health care stakeholders is never easy and that is certainly true when it comes to the use of care management tools. But if we look for areas of agreement, we can find them, especially if we focus on what makes sense clinically and for the patient. That is the focus of new research I published with my colleagues Robert Dubois and Taruja Karmarker in the Journal of Managed Care & Specialty Pharmacy which examines the care management tool, step therapy.
Given declines in drug prices, the Institute for Clinical and Economic Review’s second report on drug pricing – focusing on a hand-picked, narrow group of medicines rather than the overall landscape -- is an unnecessary and misleading exercise.
In his commentary for Chain Drug Review, NPC Interim President and Chief Executive Officer Robert Dubois, MD, PhD, explores the steps we can take to improve our current health care system in the wake of the COVID-19 pandemic.
Real-world evidence (RWE) – information collected from everyday health care experiences – is growing in availability, and many health care decision-makers are interested in understanding and using this information.